Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.53 |
| ▸ | RXRB | P28702 | 1/20 | 0.53 |
| ▸ | RXRG | P48443 | 1/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.49 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.48 |
| ▸ | BAD | Q92934 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17348353 | 0.87 | MEN1 (0.49) | RXRARXRBRXRGMAP4K4 | |
| SCHEMBL186213 | 0.85 | L3MBTL1 (0.57) | — | |
| SCHEMBL29418677 | 0.85 | L3MBTL1 (0.57) | — | |
| SCHEMBL23499863 | 0.85 | KIF11 (0.50) | MAP4K4 | |
| Hydrochloric Acid SCHEMBL21767713 | 0.84 | L3MBTL1 (0.56) | — | |
| SCHEMBL17348347 | 0.81 | — | — | |
| SCHEMBL2340659 | 0.81 | CA12 (0.53) | MAP4K4CA12CA1CA2CA9 | |
| SCHEMBL31109031 | 0.80 | NAMPT (0.46) | CA12CA1CA2CA9CA14 | |
| SCHEMBL16404616 | 0.80 | TRPV4 (0.52) | MAP4K4 | |
| SCHEMBL15006204 | 0.79 | MRGPRX4 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1960969-B | Histamine H3 receptor agents, methods of preparation and therapeutic uses thereof | LILLY CO ELI | 2012-03-28 | — | — | CN | disclosed |
| US-8008301-B2 | (2-(S)-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-(4'-trifluoromethyl-biphenyl-4-yl)-methanone; treatment of nervous system disorder, obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100048580-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | BEAVERS LISA SELSAM | 2010-02-25 | — | — | US | disclosed |
| EP-1735278-B1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2010-01-06 | — | — | EP | disclosed |
| US-7632857-B2 | (3-Fluoro-4'-methanesulfonyl-biphenyl-4-yl)-[2-(S)-(2-(R)-methyl-pyrrolidin-1-ylmethyl)-pyrrolidin-1-yl]-methanone; treatment of obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2009-12-15 | — | — | US | disclosed |
| US-7504412-B2 | Imidazopyridine derivatives | BANYU PHARMACEUTICALS, CO., LTD. (JP) | 2009-03-17 | — | — | US | disclosed |
| CN-100418965-C | Imidazopyridine derivatives | BANYU PHARMA CO LTD (JP) | 2008-09-17 | — | — | CN | disclosed |
| US-20080200494-A1 | Imidazopyridine Derivatives | MSD K.K. (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20070208024-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
| CN-1960969-A | Histamine H3 receptor agents, methods of preparation and therapeutic uses thereof | LILLY CO ELI (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1735278-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-12-27 | — | — | EP | disclosed |
| CN-1835950-A | Imidazopyridine derivatives | BANYU PHARMA CO LTD (JP) | 2006-09-20 | — | — | CN | disclosed |
| EP-1657242-A1 | IMIDAZOPYRIDINE DERIVATIVES | Banyu Pharmaceutical Co., Ltd. (JP) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005097740-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208024-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | RXRA 1948/4885RXRB 1840/4885RXRG 1561/4885 |
| US-20100048580-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | RXRA 1948/4885RXRB 1840/4885RXRG 1561/4885 |
| US-20080200494-A1 | Imidazopyridine Derivatives | MC1R, MC3R, MC5R | RXRA 972/4885RXRB 1157/4885RXRG 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.